CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 62 enrolled
Drug / intervention
MLN4924drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00677170
NCT00677170Phase 1Completed
CompareCT.gov

An Open-Label, Dose Escalation, Phase I Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients With Nonhematologic Malignancies

Millennium Pharmaceuticals, Inc.·interventional·Posted May 14, 2008·Updated Jul 16, 2013

In Brief

A Phase 1 clinical trial evaluating MLN4924 for Advanced Nonhematologic Malignancies. Completed, enrolled 62 participants across 3 sites.

Detailed Summary

This study is an open-label, multicenter, Phase 1, dose escalation study of MLN4924 in adult patients with nonhematologic malignancies. This study will be the first to administer MLN4924 in humans. The patient population will consist of adults with any form of nonhematologic malignancy for which standard, curative, life prolonging, or palliative treatment does not exist or is no longer effective.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Nonhematologic Malignancies
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 14, 2008
Enrollment StartApr 1, 2008
Primary CompletionFeb 1, 2012
Study CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 18.1 years ago

Interventions

MLN4924drug

IV dose escalation for 5 consecutive days followed by a rest period of 16 days for a 21 day cycle. Treated may continue until disease progression or unacceptable toxicity develops.